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FURIN REDUCES CARTILAGE DEGRADATION IN A MURIN MODEL OF
JOINT INSTABILITY
H. Lin 1, E. Hay 1, W. Bouaziz 1, T. Funck Brentano 1, A.M. Khatib 2,
M.E. Cohen-solal 1. 1 Inserm U606, Paris, France; 2 Inserm U1029, Bordeaux,
France
Aim of the study: Cartilage degradation in OA is mainly due to a reduced
matrix protein secretion and an increase of their degradation by matrix
metalloprotease (MMP). Indeed during OA an enhanced expression and
activation of MMPs is observed. The major MMPs involve in matrix
protein degradation are ADAMTS-4, MMP-3 or MMP-13. However, inhi-
bition of expression or activation of MMPs might reduce matrix degra-
dation during OA. Furin, a proprotein convertase, is responsible for the
conversion of various Pro-MMPs in active MMPs. Furin activates directly
ADAMTS-4 and MMP-3, while promote indirectly the maturation of
MMP-13 through other MMPs. Therefore, we hypothesised that Furin
may have an impact in matrix homeostasis in joint instability. Moreover,
we investigated the in vitro effect of Furin in MMP expression in murin
chondrocytes.
Methods: DMM (destabilisation medial meniscus) was induced surgically
by partial meniscectomy in 10-week-old C57Bl6 male mice. The day after
surgery, the mice received twice weekly intraperitoneal injections of Furin
(1U/mouse), or a1-PDX (the proprotein convertase inhibitor, 0.35 mg/g
mice), or vehicle (control group) and sacriﬁced after 6 weeks. Joint sections
were used to assess cartilage damage (OARSI score) and the number of
ADAMTS-4 and MMP-13(+) cells as well as Furin expressing cells. We
further assessed the signalling pathway induced by Furin in vitro. Murine
primary chondrocytes (pre-treated with 10ng/ml IL-1) were cultured with
Furin (10U/mL) or a1-PDX (8mM) for 48h and then analyzed the expression
of MMP-13 and the phosphorylation of Smad2/3 in cell lysates by Western
blot.
Results:We ﬁrst observed a constitutive expression of Furin in cartilage of
control mice while absent in DMM mice. Furin reduces OA score
(5.641.54) but unchangedwith a1-PDX (15.162.82) compared to vehicle
(13.921.95, p<0.02). The percentage of ADAMTS-4(+) cells was unaf-
fected by Furin or a1-PDX. However, the percentage of MMP-13(+) cells
was signiﬁcantly reduced with Furin (-76%, p<0.03) and unaffected by a1-
PDX. In vitro, Western blot analysis revealed the presence of the active
form of MMP-13 only in IL-1-activated chondrocytes compared to control
suggesting a complete maturation of MMP-13. In contrast, Furin-treated
cells showed a decrease in MMP-13 expression and maturation whereas
a1-PDX had no effect on activated chondrocytes. Moreover, Furin
enhanced the phosphorylation of SMAD2/3 suggesting the activation of
TGFb pathway.
Conclusion: In mice, Furin reduced cartilage degradation induced by DMM
as well as MMP-13 expression. Moreover, Furin decreased the in vitro
maturation of MMP-13 which might be mediated by another signalling
pathway.
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EFFICACY OF THE SELECTIVE INDUCIBLE NITRIC OXIDE SYNTHASE
INHIBITOR SD-6010 IN NONCLINICAL INFLAMMATORY, NEUROPATHIC,
AND OSTEOARTHRITIS PAIN
J.R. Connor 1, K. Rogers 2, T. Sunyer 3, M.-P. Hellio Le Graverand-
Gastineau 4, P.T. Manning 5. 1Medimmune LLC, Gaithersburg, MD, USA;
2Comentis Inc., Oklahoma City, OK, USA; 3Covidien Pharmaceuticals,
Webster Groves, MO, USA; 4 Pﬁzer Inc., Groton, CT, USA; 5Vasculox Inc., St
Louis, MO, USA
Purpose: To evaluate efﬁcacy of SD-6010, a selective inducible nitric oxide
synthase (iNOS) inhibitor, in four pain models.
Methods: Efﬁcacy of oral SD-6010 was evaluated in acute inﬂammatory
hyperalgesia (carrageenan-induced thermal hyperalgesia [CITH]);
peripheral neuropathic pain (spinal nerve ligation [SNL] and chronic
constriction injury [CCI]); and osteoarthritis (OA) pain (medial meniscal
tear [MMT]) in male Sprague-Dawley rats. In the CITH study, efﬁcacy of
oral SD-6010 (50 mg/kg or 150 mg/kg), the selective iNOS inhibitor N-iminoethyl-L-lysine (L-NIL; 30 mg/kg; positive control), or vehicle (nega-
tive control; n ¼ 6 per treatment) administered 4h after carrageenan
injection was determined by measuring paw withdrawal response to
a thermal stimulus at 1, 2, or 3 h thereafter. In studies that utilized the
other models, tactile hypersensitivity of the hindpaws was assessed by
measuring paw withdrawal threshold in response to probing with a series
of calibrated von Frey ﬁlaments applied perpendicularly to the plantar
aspect of the affected paw following oral administration of SD-6010 (SNL:
3,10, 30, or 100mg/kg, n¼6 per treatment; CCI: 3, 10, or 30 mg/kg, n¼6 per
treatment; MMT: 15, 50, or 150 mg/kg, n¼8 per treatment), gabapentin
(SNL: 3, 10, 30 or 100 mg/kg; CCI: 30 mg/kg), or vehicle (SNL only). Efﬁcacy
of SD-6010 in relieving OA-like pain in the MMT model was evaluated as
the weight bearing differential.
Results: A single dose of SD-6010 reduced acute inﬂammatory pain
(thermal hyperalgesia) in a dose-dependent manner (Figure 1). In both
models of neuropathic pain, SD-6010 produced dose-and time-depen-
dent inhibition of pain. In the SNL model, doses of SD-6010 from 10 mg/
kg to 100 mg/kg provided maximal efﬁcacy at 6 hours after adminis-
tration, comparable to gabapentin 30 mg/kg (Figure 2). Peak efﬁcacy
with both SD-6010 and gabapentin occurred between 4 and 6 hours
after administration. In the CCI model, efﬁcacy of 30 mg/kg of SD-6010
was comparable to 30 mg/kg gabapentin (Figure 3). Maximal efﬁcacy
with SD-6010 treatment occurred later than with gabapentin, but SD-
6010 duration of efﬁcacy was considerably longer in CCI. In the MMT
model of OA pain, SD-6010 also reduced tactile hypersensitivity at
doses of 50 mg/kg and 150 mg/kg and weight bearing at all doses
(Figure 4).
Conclusions: The selective iNOS inhibitor SD-6010 reduces pain in rodent
models of inﬂammatory, neuropathic, and osteoarthritis pain.Ă
